title: Efficacy of immuno-cell therapy in patients with advanced pancreatic cancer.
abstract: BACKGROUND
  Patients with advanced pancreatic carcinoma have a risk of relapse after primary therapy, and the prognosis for these patients remains bleak. The effect of immuno-cell therapy in advanced pancreatic carcinoma, with or without other standard therapies, was examined.
  
  
  METHODS
  Forty-six patients with advanced pancreatic carcinoma, undergoing immuno-cell treatment, were evaluated.
  
  
  RESULTS
  Of all the patients, those who received immuno-cell therapy alone accounted for 15.4% of partial response (PR), 23.1% of long-term stable disease (SD), 46.2% of SD and 15.4% of progressive disease (PD), and had a 50% survival time of 14.5 months. The respective values for the 28 patients undergoing immuno-cell therapy with gemcitabine were 10.7% of PR, 10.7% of long-term SD, 32.1% of SD and 46.4% of PD, with a 50% survival time of 15.8 months; for 5 patients undergoing immuno-cell therapy with UFT or TS-1, the values were 0% of PR, 0% of SD, 20.0% of SD and 80.0% of PD, with a 50% survival time of 16.1 months.
  
  
  CONCLUSIONS
  The combination of immuno-cell therapies with standard therapies may be effective in the short-term in patients with advanced pancreatic cancer. Long-term survival depends on the presence of metastases and the duration of coadministration with these standard therapies.
authors.affiliation: Shin-yokohama Medical Clinic, Usui Building 3F, 2-5-14 Shin-yokohama, Kohoku-ku,Yokohama-shi, Kanagawa, 222-0033, Japan. kaneko@j-immunother.com
authors.forename: Toru
authors.initials: T
authors.lastname: Kaneko
authors.forename: Shigenori
authors.initials: S
authors.lastname: Goto
authors.forename: Akira
authors.initials: A
authors.lastname: Kato
authors.forename: Akiteru
authors.initials: A
authors.lastname: Akeyama
authors.forename: Masamichi
authors.initials: M
authors.lastname: Tomonaga
authors.forename: Katsunada
authors.initials: K
authors.lastname: Fujimoto
authors.forename: Yoju
authors.initials: Y
authors.lastname: Miyamoto
authors.forename: Masazumi
authors.initials: M
authors.lastname: Eriguchi
authors.forename: Koji
authors.initials: K
authors.lastname: Egawa
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003713:Dendritic Cells / Q000276:immunology; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000009:adverse effects / Q000379:methods*; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine